Pfizer rolls out another cost-cutting program, sets $1.5 billion …
WEBMay 23, 2024 · U.S. drugmaker Pfizer on Wednesday launched a new multi-year program to reduce its expenses by about $1.5 billion by the end of 2027, adding on to a $4 billion cost cutting plan it announced last...
Newsroom | Pfizer
WEBPfizer is showcasing new research across the company’s key tumor areas and core scientific modalities, including small molecules, antibody-drug conjugates and bispecific antibodies. Find Out More
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full …
WEBDec 11, 2020 · COMIRNATY is the first COVID-19 vaccine to be granted FDA approval. Approval is based on a comprehensive submission package including six-month efficacy and safety data after second dose. More than 1.2 billion Pfizer-BioNTech doses have been delivered to more than 120 countries or territories around the world since December 2020.
CDC identifies possible safety issue with Pfizer’s updated ... - CNN
WEBJan 13, 2023 · The US Centers for Disease Control and Prevention said Friday that there is a possible safety issue with the bivalent Covid-19 vaccine made by Pfizer and BioNTech but that it is unlikely to ...
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High …
WEBSep 22, 2021 · NEW YORK & MAINZ, Germany-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced topline results from a Phase 3 randomized, controlled trial evaluating the efficacy and safety of a 30-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine in more than 10,000 individuals 16 years of age …
Press Releases | Pfizer
WEB6 days ago · Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma.
Pfizer pins hopes on record pipeline to recover from post-Covid …
WEBFeb 21, 2023 · Pfizer expects sales of Comirnaty, the Covid vaccine it developed with German company BioNTech, and its antiviral pill Paxlovid, to fall 62 per cent to $21.5bn in 2023, compared to last year.
Pfizer and BioNTech Announce Vaccine Candidate Against COVID …
WEBNov 9, 2020 · NEW YORK & MAINZ, GERMANY-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the …
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 …
WEBJun 25, 2022 · Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels; bivalent vaccine candidate exhibited a 9.1 and 10.9-fold increase against Omicron Geometric mean ratios for Omicron neutralizing antibody …
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 …
WEBNov 18, 2020 · Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose;170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group. Efficacy was consistent across age, gender, race and ethnicity demographics; observed …